Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib

NCT00320918 is registered in ClinicalTrials.gov with University of New Mexico as lead sponsor.

NCT NCT00320918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00320918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib
Lead sponsor
University of New Mexico
Phase
Observational
Overall status
Terminated
Start date
November 30, 2005
Completion date
October 31, 2006
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma